InterMune PT Raised to $55.00 at JMP Securities (ITMN)
Equities researchers at JMP Securities raised their price target on shares of InterMune (NASDAQ:ITMN) from $48.00 to $55.00 in a research report issued on Thursday. JMP Securities’ target price indicates a potential upside of 30.83% from the company’s current price.
InterMune (NASDAQ:ITMN) traded up 3.75% during mid-day trading on Thursday, hitting $43.618. The stock had a trading volume of 1,235,499 shares. InterMune has a one year low of $9.32 and a one year high of $42.68. The stock has a 50-day moving average of $36.54 and a 200-day moving average of $25.31. The company’s market cap is $4.313 billion.
InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was up 188.6% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.32 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ITMN. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of InterMune in a research note on Tuesday. They now have a $51.00 price target on the stock, up previously from $45.00. Separately, analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Finally, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $42.85.
In other InterMune news, CEO Daniel G. Welch unloaded 3,914 shares of InterMune stock on the open market in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $39.19, for a total transaction of $153,389.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.